CLMT as reported
Calumet, Inc. reported $4.17B of revenue over the trailing twelve months, −0.11% on the year before. 10 reported series are charted on this page, each one as filed.
$4.17B
Revenue, trailing twelve months · to Q1 2026 · −0.11% against the twelve months before
- Net Income
- −$189M
Net Income · −45% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$16M
Free Cash Flow · −76% year on year · trailing twelve months to Q1 2026
- Op Margin
- −0.68%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $4.17B | −0.11% | Q1 2026 |
| Net Income | −$189M | −45% | Q1 2026 |
| EPS | −$2.16 | −46% | Q1 2026 |
| Gross Margin | 5.4% | n/a | Q1 2026 |
| Op Margin | −0.68% | n/a | Q1 2026 |
| Net Margin | −4.9% | n/a | Q1 2026 |
| ROE | 18% | n/a | Q1 2026 |
| ROA | −6.4% | n/a | Q1 2026 |
| ROIC | 0.89% | n/a | Q1 2026 |
| Free Cash Flow | −$16M | −76% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Calumet, Inc. (CLMT) - Revenue & ProfitRevenue & ProfitCalumet, Inc. (CLMT)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Specialty Chemicals
Ranks #32 of 36 by Smart Score